Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial

Article Oncology

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

George D. Demetri et al.

Summary: This study provides additional evidence on the safety and efficacy of Entrectinib in treating NTRK fusion-positive solid tumors, with prolonged follow-up and an increased number of patients.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Review Oncology

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Aaron C. Tan et al.

Summary: The therapeutic landscape of non-small-cell lung cancer is undergoing significant changes with the shift from histology-based classification to molecularly defined subsets. Targeted therapies for specific driver mutations such as EGFR, ALK, and ROS1 have shown promising results, and there is a growing list of approved therapies for other mutations. The importance of diagnostic molecular testing, optimal sequencing of therapies, application of targeted therapies in early-stage disease, and the impact of genomic mutations on targeted therapy efficacy are important areas of research.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors

Fen Yang et al.

Summary: A population pharmacokinetic model was developed to provide optimal dosing regimen for further development of TQ-B3101 in pediatric patients with anaplastic large cell lymphoma.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Oncology

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report

Konstantinos Christofyllakis et al.

Summary: Lung cancer is the leading cause of cancer-related deaths worldwide, but older adults are often overlooked in clinical trials. This review summarizes the evidence of treatment for older patients with targetable driver mutations or alterations in lung cancer and provides insights from a geriatric oncology perspective.

JOURNAL OF GERIATRIC ONCOLOGY (2022)

Add to Collection

Article Oncology

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date

Sebastien Gendarme et al.

Summary: The ROS-1 gene is pivotal in the oncogenesis of various tumors, and targeting ROS-1 with tyrosine kinase inhibitors can effectively inhibit tumor growth. Crizotinib is the current first-line therapy with promising results, but newer ROS-1-targeting TKIs have been developed for improved efficacy.

CURRENT ONCOLOGY (2022)

Add to Collection

Review Oncology

ROS1-dependent cancers - biology, diagnostics and therapeutics

Alexander Drilon et al.

Summary: The proto-oncogene ROS1 encodes a receptor tyrosine kinase without a well-defined physiological role, and somatic chromosomal fusions involving ROS1 lead to chimeric oncoproteins that drive various cancers. Although ROS1-directed tyrosine kinase inhibitors show therapeutic efficacy, resistance mechanisms remain unclear.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Rafal Dziadziuszko et al.

Summary: Entrectinib continues to show a high level of clinical benefit for patients with ROS1 fusion-positive NSCLC, including those with central nervous system metastases.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

Wei Cao et al.

Summary: This study summarized the recent changing profiles of cancer burden worldwide and in China, revealing that breast cancer became the most diagnosed cancer globally in 2020. China accounted for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020, with a high cancer mortality rate.

CHINESE MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Yongchang Zhang et al.

Summary: Our study demonstrates that baseline brain metastatic status and various molecular factors may contribute to distinct clinical outcomes from first-line crizotinib therapy in patients with ROS1-rearranged lung cancer.

BMC MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Toward personalized treatment approaches for non-small-cell lung cancer

Meina Wang et al.

Summary: Over the past two decades, molecular targeted therapies and immunotherapies have significantly improved outcomes for non-small-cell lung cancer (NSCLC), but the majority of advanced NSCLCs eventually become resistant. The future challenge lies in the application of predictive biomarkers for patient stratification in order to better manage NSCLC.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal